NCT lookup

Inclusion criteria:

* Diagnosis of rheumatoid arthritis (RA) ≥ 3 months.
* Moderately to severely active rheumatoid arthritis.
* Participants who per investigator judgment were incomplete responders to at least 12 weeks of an adequate dose of continuous treatment with or who were intolerant of one or a combination of non-biologic disease modifying anti-rheumatic drugs (DMARDs).

Exclusion criteria:

* Participants \< 18 years of age.
* Past history of, or current, autoimmune or inflammatory systemic or localized joint disease(s) other than RA.
* History of juvenile idiopathic arthritis or arthritis onset prior to age 16.
* Severe active systemic RA, including but not limited to vasculitis, pulmonary fibrosis, and/or Felty's syndrome.
* Prior treatment with any biologic anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonist therapies.
* Treatment with prednisone \> 10 mg or equivalent per day, or change in dosage within 4 weeks prior to randomization.
* New treatment with or dose-adjustment of on-going nonsteroidal anti-inflammatory drug (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors within 4 weeks prior to randomization, except for the use of low-dose acetylsalicylic acid for cardiovascular diseases.
* Use of parenteral glucocorticoids or intra-articular glucocorticoids injection within 4 weeks prior to randomization.
* Prior treatment with a Janus kinase (JAK) inhibitor (tofacitinib).
* New treatment or dose-adjustment to on-going medication for dyslipidemia, such as statin, within 6 weeks prior to randomization.
* Participation in any clinical research study evaluating another investigational drug or therapy within 5 half-lives or 60 days of first dose of study drug administration, whichever is longer.
* Participants with a history of malignancy other than adequately-treated carcinoma in-situ of the cervix, non-metastatic squamous cell or basal cell carcinoma of the skin, within 5 years prior to the randomization visit. Non-malignant lymphoproliferative disorders are also excluded.
* Participants with active tuberculosis or untreated latent tuberculosis infection.
* Pregnant or breast feeding women.

The above information is not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.

• Gilbert, Arizona, United States
• Upland, California, United States
• South Miami, Florida, United States
• Elizabethtown, Kentucky, United States
• Minot, North Dakota, United States
• Oklahoma City, Oklahoma, United States
• Tulsa, Oklahoma, United States
• Duncansville, Pennsylvania, United States
• Jackson, Tennessee, United States
• Amarillo, Texas, United States
• Mesquite, Texas, United States
• Clarksburg, West Virginia, United States
• Franklin, Wisconsin, United States
• Santiago, Chile
• Pardubice, Czechia
• Prague, Czechia
• Uherské Hradiště, Czechia
• Tallinn, Estonia
• Tallinn, Estonia
• Budapest, Hungary
• Budapest, Hungary
• Esztergom, Hungary
• Poznan, Poland
• Warsaw, Poland
• Wroclaw, Poland
• Kemerovo, Russia
• Moscow, Russia
• Ryazan, Russia